肝细胞癌分子治疗:突破传统框架的探索
本综述回顾了不可切除肝细胞癌(HCC)系统治疗的最新进展,包括乐伐替尼对比索拉非尼的非劣效结果、瑞戈非尼/卡博替尼/雷莫芦单抗在索拉非尼失败后的优势,以及免疫检查点抑制剂的疗效信号;并讨论了抗血管生成药物与免疫治疗联合的协同假说及针对TGF-β、MET、FGFR4等新靶点的分子治疗。
要点
- 乐伐替尼对比索拉非尼非劣效,瑞戈非尼/卡博替尼/雷莫芦单抗在索拉非尼失败后优于安慰剂。
- 免疫检查点抑制剂显示鼓舞性疗效信号,但除甲胎蛋白用于筛选雷莫芦单抗外缺乏其他生物标志物。
- 抗血管生成药物与免疫治疗联合的I期研究初步结果积极,已推动一线III期试验设计。
核心结论
- 索拉非尼曾是不可切除HCC唯一有临床疗效的系统药物,近年乐伐替尼显示非劣效,瑞戈非尼、卡博替尼和雷莫芦单抗在索拉非尼失败后优于安慰剂。
- 免疫检查点抑制剂报告了鼓舞性疗效信号,但除甲胎蛋白用于筛选雷莫芦单抗外,尚无生物标志物可识别特定治疗应答者。
- 抗血管生成药物与免疫治疗联合的协同假说正在多项临床试验中验证,I期研究初步结果积极。
研究设计与样本
- 本综述讨论了不可切除HCC分子治疗的最新数据,包括新型联合策略和新靶点。
- 综述整合了多项临床试验结果,涉及索拉非尼、乐伐替尼、瑞戈非尼、卡博替尼、雷莫芦单抗及免疫检查点抑制剂。
- 综述还纳入了针对TGF-β、MET(肝细胞生长因子受体)和FGFR4等新靶点的II期研究。
主要发现
- 乐伐替尼对比索拉非尼显示非劣效。
- 瑞戈非尼、卡博替尼和雷莫芦单抗在索拉非尼失败患者中优于安慰剂。
- 免疫检查点抑制剂试验报告了鼓舞性疗效信号。
- 贝伐珠单抗联合阿替利珠单抗及乐伐替尼联合帕博利珠单抗的I期研究初步结果积极,已推动III期试验设计。
- 针对TGF-β、MET和FGFR4等新靶点的II期研究整合了转化研究以定义肿瘤生物学特征并识别肿瘤和血液生物标志物。
关键数值与推荐
- 甲胎蛋白用于筛选适合雷莫芦单抗治疗的患者。
- 除甲胎蛋白外,尚无生物标志物可用于识别对特定治疗可能应答的患者。
- 抗血管生成药物与免疫检查点抑制剂联合的III期试验正在一线治疗中开展。
临床怎么用
- 对于不可切除HCC,索拉非尼和乐伐替尼可作为一线系统治疗选择。
- 索拉非尼失败后可考虑瑞戈非尼、卡博替尼或雷莫芦单抗(后者需根据甲胎蛋白筛选)。
- 抗血管生成药物与免疫治疗联合是未来一线治疗的重要研究方向,有待III期试验结果确认。
局限性
- 除甲胎蛋白外缺乏可用的生物标志物来指导特定分子治疗的病人选择。
- 抗血管生成药物与免疫治疗联合的协同作用仍处于假说验证阶段,尚无III期结果。
- 针对TGF-β、MET和FGFR4等新靶点的研究仍处于II期阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the past decade, sorafenib has been the only systemic agent with proven clinical efficacy for patients with unresectable hepatocellular carcinoma (HCC). Recently, lenvatinib was shown to be non-inferior to sorafenib, while regorafenib, cabozantinib, and ramucirumab were shown to be superior to placebo in patients failing sorafenib. In addition, trials of immune checkpoint inhibitors reported encouraging efficacy signals. However, apart from alpha-fetoprotein, which is used to select patients for ramucirumab, no biomarkers are available to identify patients that may respond to a specific treatment. Different synergisms have been postulated based on the potential interplay between antiangiogenic drugs and immunotherapy, with several clinical trials currently testing this hypothesis. Indeed, encouraging preliminary results of phase I studies of bevacizumab plus atezolizumab and lenvatinib plus pembrolizumab have led to the design of ongoing phase III trials, including both antiangiogenics and immune checkpoint inhibitors in the front-line setting. Other important phase II studies have tested molecular therapies directed against different novel targets, such as transforming growth factor-beta, MET (hepatocyte growth factor receptor), and fibroblast growth factor receptor 4. These studies integrated translational research with the aim of better defining the biological tumour profile and identifying tumour and blood biomarkers that select patients who may really benefit from a specific molecular therapy. Importantly, good safety profiles make these drugs suitable for future combinations. In this review, we discuss the most recent data on novel combination strategies and targets, as well as looking ahead to the future role of molecular therapies in the treatment of patients with advanced HCC.
引用
- Faivre S, Rimassa L, Finn RS, et al. Molecular therapies for HCC: Looking outside the box. J Hepatol. 2020. PMID: 31954496. doi:10.1016/j.jhep.2019.09.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。